The immuno-oncological challenge of COVID-19.
Nat Cancer
; 1(10): 946-964, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-834917
ABSTRACT
Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Nat Cancer
Year:
2020
Document Type:
Article
Affiliation country:
S43018-020-00122-3
Similar
MEDLINE
...
LILACS
LIS